Metalloproteases/anti-metalloproteases imbalance in chronic obstructive pulmonary disease: Genetic factors and treatment implications

Current Opinion in Pulmonary Medicine

Volumn 17, Issue SUPPL. 1, 2011, Pages

  Mocchegiani, Eugenio ^a   Giacconi, Robertina ^a   Costarelli, Laura ^a  

^a INRCA   (Italy)

Author keywords

2 macroglobulin; lung function; matrix metalloproteases; polymorphisms; tissue inhibitors of MMPs

Indexed keywords

ADAM PROTEIN; ALPHA 2 MACROGLOBULIN; DISINTEGRIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; DRUG EFFICACY; EXTRACELLULAR MATRIX; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENE FREQUENCY; GENE THERAPY; GENETIC POLYMORPHISM; HEREDITY; HUMAN; LUNG FUNCTION;

ADAM PROTEINS; AGED; AGED, 80 AND OVER; AGING; ALPHA-MACROGLOBULINS; EMPHYSEMA; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MATRIX METALLOPROTEINASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; TISSUE INHIBITOR OF METALLOPROTEINASES; VITAL CAPACITY;

EID: 84855413331     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/01.mcp.0000410743.98087.12     Document Type: Article

References (84)

1. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 2004; 350:2689-2697.
2. Huertas A, Palange P. COPD: a multifactorial systemic disease. Ther Adv Respir Dis 2011; 5:217-224.
3. Fabbri LM, Hurd SS, GOLD Scientific Committee. Global strategy for the diagnosis, management and prevention of COPD: 2003 update. Eur Respir J 2003; 22:1-2. (Pubitemid 36896461)
4. Barnes PJ. Therapy of chronic obstructive pulmonary disease. Pharmacol Ther 2003; 97:87-94. (Pubitemid 35477805)
5. Hersh CP, Hokanson JE, Lynch DA et al. Family history is a risk factor for COPD. Chest 2011; 140:343-350.
6. Løkke A, Lange P, Scharling H et al. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61:935-939. (Pubitemid 44787161)
7. Obeidat M, Wain LV, Shrine N et al. A comprehensive evaluation of potential lung function associated genes in the SpiroMeta general population sample. PLoS One 2011; 6:e19382.
8. Castaldi PJ, Cho MH, Litonjua AA et al. The association of genome-wide significant spirometric loci with COPD susceptibility. Am J Respir Cell Mol Biol 2011; 45:1147-1153.
9. Lipman PJ, Cho MH, Bakke P et al. On the follow-up of genome-wide association studies: an overall test for the most promising SNPs. Genet Epidemiol 2011; 35:303-309.
10. Gó rska K, Maskey-Warzechowska M, Krenke R. Airway inflammation in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2010; 16:89-96.
11. Laurell CB, Eriksson S. Hypo-alpha-1-antitrypsinemia. Verh Dtsch Ges Inn Med 1964; 70:537-539.
12. Flannery CR. MMPs and ADAMTS: functional studies. Front Biosci 2006; 11:544-569.
13. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006; 11:1696-1701. (Pubitemid 43253387)
14. Shapiro SD, Kobayashi DK, Ley TJ. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem 1993; 268:23824-23829. (Pubitemid 23335353)
15. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997; 277:2002-2004. (Pubitemid 27449144)
16. Yanbaeva DG, Dentener MA, Creutzberg EC et al. Systemic effects of smoking. Chest 2007; 131:1557-1566. (Pubitemid 46762366)
17. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behaviour. Annu Rev Cell Dev Biol 2001; 17:463-516. (Pubitemid 33096184)
18. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2:161-174. (Pubitemid 37328786)
19. Sato H, Takino T, Okada Y et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370:61-65. (Pubitemid 24216953)
20. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodelling and vascular disease. Biochem Pharmacol 2008; 75:346-359. (Pubitemid 350298459)
21. Imai K, Dalal SS, Chen ES et al. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit Care Med 2001; 163:786-789.
22. Baraldo S, Bazzan E, Zanin ME et al. Matrix metalloproteinase-2 protein in lung periphery is related to COPD progression. Chest 2007; 132:1733-1740.
23. Joos L, He JQ, Shepherdson MB et al. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 2002; 11:569-576. (Pubitemid 34257493)
24. Lee SY, Kim MJ, Kang HG et al. Polymorphisms in matrix metalloproteinase-1,-9 and-12 genes and the risk of chronic obstructive pulmonary disease in a Korean population. Respiration 2010; 80:133-138.
25. Haq I, Chappell S, Johnson SR et al. Association of MMP-2 polymorphisms with severe and very severe COPD: a case control study of MMPs-1, 9 and 12 in a European population. BMC Med Genet 2010; 11:7-12.
26. van Diemen CC, Postma DS, Siedlinski M et al. Genetic variation in TIMP1 but not MMPs predict excess FEV1 decline in two general population-based cohorts. Respir Res 2011; 12:57-60.
27. Ito I, Nagai S, Handa T et al. Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. Am J Respir Crit Care Med 2005; 172:1378-1382. (Pubitemid 43069810)
28. Minematsu N, Nakamura H, Tateno H et al. Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. Biochem Biophys Res Commun 2001; 289:116-119. (Pubitemid 33108801)
29. Zhou M, Huang SG, Wan HY et al. Genetic polymorphism in matrix metalloproteinase-9 and the susceptibility to chronic obstructive pulmonary disease in Han population of south China. Chin Med J (Engl) 2004; 117:1481-1484. (Pubitemid 39530225)
30. Wood AM, Stockley RA. The genetics of chronic obstructive pulmonary disease. Respir Res 2006; 7:130-133.
31. Shipley JM, Wesselschmidt RL, Kobayashi DK et al. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci USA 1996; 93:3942-3946. (Pubitemid 26144227)
32. Shapiro SD, Kobayashi DK, Ley TJ. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem 1993; 268:23824-23849.
33. Nénan S, Boichot E, Lagente V, Bertrand CP. Macrophage elastase (MMP-12): a pro-inflammatory mediator? Mem Inst Oswaldo Cruz 2005; 100:167-172. (Pubitemid 40685458)
34. Qu P, Du H, Wang X, Yan C. Matrix metalloproteinase 12 overexpression in lung epithelial cells plays a key role in emphysema to lung bronchioalveolar adenocarcinoma transition. Cancer Res 2009; 69:7252-7261.
35. Churg A, Wang RD, Tai H et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-{alpha} release. Am J Respir Crit Care Med 2003; 167:1083-1089. (Pubitemid 36459653)
36. Jormsjö S, Ye S, Moritz J et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 2000; 86:998-1003. (Pubitemid 30324313)
37. Hunninghake GM, Cho MH, Tesfaigzi Y et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med 2009; 361:2599-2608.
38. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003; 17:7-30. (Pubitemid 36062504)
39. Black RA, White JM. ADAMs: focus on protease domain. Curr Opin Cell Biol 1998; 10:654-659.
40. Garlisi CG, Zou J, Devito KE et al. Human ADAM33: protein maturation and localization. Biochem Biophys Res Commun 2003; 301:35-43. (Pubitemid 36268844)
41. Paulissen G, Rocks N, Gueders MM et al. Role of ADAM and ADAMTS metalloproteinases in airway diseases. Respir Res 2009; 10:127-130.
42. Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008; 8:929-941.
43. Weskamp G, Ford JW, Sturgill J et al. ADAM10 is a principal 'sheddase' of the low-affinity immunoglobulin E receptor CD23. Nat Immunol 2006; 7:1293-1298. (Pubitemid 46111250)
44. Jie Z, Jin M, Cai Y et al. The effects of Th2 cytokines on the expression of ADAM33 in allergen-induced chronic airway inflammation. Respir Physiol Neurobiol 2009; 168:289-294.
45. Gosman MM, Boezen HM, van Diemen CC et al. A disintegrin and metalloprotease 33 and chronic obstructive pulmonary disease pathophysiology. Thorax 2007; 62:242-247. (Pubitemid 46579805)
46. Zou J, Zhu F, Liu J et al. Catalytic activity of human ADAM33. J Biol Chem 2004; 279:9818-9830. (Pubitemid 38372580)
47. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002; 115:3719-3727. (Pubitemid 35203598)
48. Puxeddu I, Pang YY, Harvey A et al. The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol 2008; 121:1400-1406.
49. van Diemen CC, Postma DS, Vonk JM et al. A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. Am J Resp Crit Care Med 2005; 172:329-333. (Pubitemid 41026143)
50. Wang X, Li L, Xiao J et al. Association of ADAM33 gene polymorphisms with COPD in a north eastern Chinese population. BMC Med Genet 2009; 10:132-133.
51. Sadeghnejad A, Ohar JA, Zheng SL et al. Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers. Respir Res 2009; 10:21-24.
52. Ju CR, Xia XZ, Chen RC. Expressions of tumor necrosis factor converting enzyme and ErbB3 in rats with chronic obstructive pulmonary disease. Chin Med J 2007; 120:1505-1510.
53. Shao MX, Nakanaga T, Nadel JA. Cigarette smoke induces MUC5AC mucin overproduction via tumor necrosis factoralpha-converting enzyme in human airway epithelial (NCIH292) cells. Am J Physiol Lung Cell Mol Physiol 2004; 287:L420-427. (Pubitemid 38943925)
54. MurphyG, Docherty AJ. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992; 7:120-125.
55. Hirano K, Sakamoto T, Uchida Y et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 2001; 18:748-752. (Pubitemid 33076914)
56. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343:269-280. (Pubitemid 30490396)
57. Hegab AE, Sakamoto T, Uchida Y et al. Association analysis of tissue inhibitor of metalloproteinase2 gene polymorphisms with COPD in Egyptians. Respir Med 2005; 99:107-110. (Pubitemid 40017393)
58. Hegab AE, Sakamoto T, Uchida Y et al. Promoter activity of human tissue inhibitor of metalloproteinase 2 gene with novel single nucleotide polymorphisms. Respirology 2005; 10:27-30. (Pubitemid 40343758)
59. Kumar M, Bhadoria DP, Dutta K et al. Combinatorial effect of TIMP-1 and a(1)AT gene polymorphisms on development of chronic obstructive pulmonary disease. Clin Biochem 2011; 44:1067-1073.
60. Chu CT, Howard GC, Misra UK, Pizzo SV. Alpha 2-macroglobulin: a sensor for proteolysis. Ann N Y Acad Sci 1994; 737:291-307.
61. Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 1989; 264:11539-11542. (Pubitemid 19185316)
62. Strickland DK, Ashcom JD, Williams S et al. Sequence identity between the alpha 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this molecule is a multifunctional receptor. J Biol Chem 1990; 265:17401-17404.
63. Williams SE, Ashcom JD, Argraves WS et al. A novel mechanism for controlling the activity of alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptorassociated protein. J Biol Chem 1992; 267:9035-9040.
64. El-Attar M, Said M, El-Assal G et al. Serum trace element levels in COPD patients: the relation between trace element supplementation and period of mechanical ventilation in a randomized controlled trial. Respirology 2009; 14:180-1187.
65. Mocchegiani E, Muzzioli M, Cipriano C et al. Zinc, T-cell pathways, ageing: role of metallothioneins. Mech Ageing Dev 1998; 106:183-204. (Pubitemid 28559284)
66. Verrills NM, Irwin JA, He XY et al. Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 183:1633-1643.
67. Kancha RK, Stearns ME, Hussain MM. Decreased expression of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor in invasive cell clones derived from human prostate and breast tumor cells. Oncol Res 1994; 6:365-372. (Pubitemid 24371422)
68. Mocchegiani E, Ciavattini A, Santarelli L et al. Role of zinc and alpha2 macroglobulin on thymic endocrine activity and on peripheral immune efficiency (natural killer activity and interleukin 2) in cervical carcinoma. Br J Cancer 1999; 79:244-250. (Pubitemid 29002292)
69. Hua H, Li M, Luo T et al. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci 2011; 68:3853-3868.
70. Poller W, Faber JP, Klobeck G, Olek K. Cloning of the human alpha 2-macroglobulin gene and detection of mutations in two functional domains: the bait region and the thiolester site. Hum Genet 1992; 88:313-319.
71. Lin M, Sutherland DR, Horsfall W et al. Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 2002; 99:1683-1691. (Pubitemid 34533042)
72. Jä rvinen AK, Autio R, Kilpinen S et al. High-resolution copy number and gene expression microarray analyses of head and neck squamous cell carcinoma cell lines of tongue and larynx. Genes Chromosomes Cancer 2008; 47:500-509. (Pubitemid 351657185)
73. Iwahashi K, Aoki J. A review of smoking behavior and smokers evidence (chemical modification, inducing nicotine metabolism, and individual variations by genotype: dopaminergic function and personality traits). Drug Chem Toxicol 2009; 32:301-306.
74. Hoekstra R, Eskens FA, Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist 2001; 6:415-427. (Pubitemid 33022212)
75. Bissett D, O'Byrne KJ, von Pawel J et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in nonsmall-cell lung cancer. J Clin Oncol 2005; 23:842-849. (Pubitemid 46224184)
76. Jiang Y, Wang M, Celiker MY et al. Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res 2001; 61:2365-2370. (Pubitemid 32685806)
77. Li W, Li J, Wu Y et al. A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3- methylbutanoic acid (MMP408). J Med Chem 2009; 52:1799-1802.
78. Mukhopadhyay S, Sypek J, Tavendale R et al. Matrix metalloproteinase-12 is a therapeutic target for asthma in children and young adults. J Allergy Clin Immunol 2010; 126:70.e16-76.e16.
79. Chetty C, Rao JS, Lakka SS. Matrix metalloproteinase pharmacogenomics in nonsmall-cell lung carcinoma. Pharmacogenomics 2011; 12:535-546.
80. Cazzola M, Dahl R. Inhaled combination therapy with long-acting beta 2-agonists and corticosteroids in stable COPD. Chest 2004; 126:220-237. (Pubitemid 38943141)
81. Hersh CP. Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities. Pharmacogenomics 2010; 11:237-247.
82. Martinez FJ, Donohue JF, Rennard SI. Chronic Obstructive Pulmonary Disease 2. The future of chronic obstructive pulmonary disease treatment-difficulties of and barriers to drug development. Lancet 2011; 378:1027-1037.
83. Liu G, Men P, Perry G et al. Nanoparticles and iron chelators as a potential novel Alzheimer therapy. Methods Mol Biol 2010; 610:123-144.
84. Tallant C, Marrero A, Gomis-Rü th FX. Matrix metalloproteinases: fold and function of their catalytic domains. Biochim Biophys Acta 2010; 1803:20-28.